# Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.

> **NCT05922813** · PHASE1 · COMPLETED · sponsor: **BMI Korea** · enrollment: 257 (actual)

## Conditions studied

- Health, Subjective

## Interventions

- **BIOLOGICAL:** BMI2004
- **OTHER:** 0.9% NaCl

## Key facts

- **NCT ID:** NCT05922813
- **Lead sponsor:** BMI Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-30
- **Primary completion:** 2023-03-10
- **Final completion:** 2023-04-12
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2023-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05922813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05922813, "Evaluate the Safety and Tolerability of a Single-dose Administration of BMI2004 Inj.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05922813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*